154 related articles for article (PubMed ID: 24418857)
1. Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies.
Ross JS; Wang K; Rand JV; Sheehan CE; Jennings TA; Al-Rohil RN; Otto GA; Curran JC; Palmer G; Downing SR; Yelensky R; Lipson D; Balasubramanian S; Garcia L; Mahoney K; Ali SM; Miller VA; Stephens PJ
Am J Surg Pathol; 2014 Feb; 38(2):235-8. PubMed ID: 24418857
[TBL] [Abstract][Full Text] [Related]
2. Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II.
Hanna GJ; Grover P; Elliott A; McGrath J; Xiu J; Sukari A; Johnson JM; Wise-Draper T
Clin Cancer Res; 2024 May; 30(10):2225-2232. PubMed ID: 38416410
[TBL] [Abstract][Full Text] [Related]
3. Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling.
Chae YK; Chung SY; Davis AA; Carneiro BA; Chandra S; Kaplan J; Kalyan A; Giles FJ
Oncotarget; 2015 Nov; 6(35):37117-34. PubMed ID: 26359351
[TBL] [Abstract][Full Text] [Related]
4. Global mutational profiling of formalin-fixed human colon cancers from a pathology archive.
Adams MD; Veigl ML; Wang Z; Molyneux N; Sun S; Guda K; Yu X; Markowitz SD; Willis J
Mod Pathol; 2012 Dec; 25(12):1599-608. PubMed ID: 22878650
[TBL] [Abstract][Full Text] [Related]
5. Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics.
Cohen PR; Tomson BN; Elkin SK; Marchlik E; Carter JL; Kurzrock R
Oncotarget; 2016 Apr; 7(17):23454-67. PubMed ID: 26981779
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population.
Lu Q; Wang N; Jiang K; Zhou H; Zhang P; Zhang J; Wang S; Sun P; Xu F
ESMO Open; 2024 Mar; 9(3):102389. PubMed ID: 38460250
[TBL] [Abstract][Full Text] [Related]
7. Oncologist use and perception of large panel next-generation tumor sequencing.
Schram AM; Reales D; Galle J; Cambria R; Durany R; Feldman D; Sherman E; Rosenberg J; D'Andrea G; Baxi S; Janjigian Y; Tap W; Dickler M; Baselga J; Taylor BS; Chakravarty D; Gao J; Schultz N; Solit DB; Berger MF; Hyman DM
Ann Oncol; 2017 Sep; 28(9):2298-2304. PubMed ID: 28911072
[TBL] [Abstract][Full Text] [Related]
8. Targeted Sequencing Revealed Distinct Mutational Profiles of Ocular and Extraocular Sebaceous Carcinomas.
Na HY; Park JH; Shin SA; Lee S; Lee H; Chae H; Choung H; Kim N; Chung JH; Kim JE
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638295
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of pancreatic cancer specimens for comprehensive genomic profiling.
Washimi K; Hiroshima Y; Sato S; Ueno M; Kobayashi S; Yamamoto N; Hasegawa C; Yoshioka E; Ono K; Okubo Y; Yokose T; Miyagi Y
Pathol Int; 2024 Mar; ():. PubMed ID: 38477638
[TBL] [Abstract][Full Text] [Related]
10. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations.
Mitani Y; Liu B; Rao PH; Borra VJ; Zafereo M; Weber RS; Kies M; Lozano G; Futreal PA; Caulin C; El-Naggar AK
Clin Cancer Res; 2016 Feb; 22(3):725-33. PubMed ID: 26631609
[TBL] [Abstract][Full Text] [Related]
11. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.
Ross JS; Badve S; Wang K; Sheehan CE; Boguniewicz AB; Otto GA; Yelensky R; Lipson D; Ali S; Morosini D; Chliemlecki J; Elvin JA; Miller VA; Stephens PJ
Arch Pathol Lab Med; 2015 May; 139(5):642-9. PubMed ID: 25927147
[TBL] [Abstract][Full Text] [Related]
12. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
Ross JS; Wang K; Gay L; Al-Rohil R; Rand JV; Jones DM; Lee HJ; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Morosini D; Hawryluk M; Catenacci DV; Miller VA; Churi C; Ali S; Stephens PJ
Oncologist; 2014 Mar; 19(3):235-42. PubMed ID: 24563076
[TBL] [Abstract][Full Text] [Related]
13. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
[TBL] [Abstract][Full Text] [Related]
14. Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.
Ross JS; Wang K; Rand JV; Gay L; Presta MJ; Sheehan CE; Ali SM; Elvin JA; Labrecque E; Hiemstra C; Buell J; Otto GA; Yelensky R; Lipson D; Morosini D; Chmielecki J; Miller VA; Stephens PJ
J Clin Pathol; 2014 Nov; 67(11):968-73. PubMed ID: 25078331
[TBL] [Abstract][Full Text] [Related]
15. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
16. Genomic landscape of adenoid cystic carcinoma of the breast.
Martelotto LG; De Filippo MR; Ng CK; Natrajan R; Fuhrmann L; Cyrta J; Piscuoglio S; Wen HC; Lim RS; Shen R; Schultheis AM; Wen YH; Edelweiss M; Mariani O; Stenman G; Chan TA; Colombo PE; Norton L; Vincent-Salomon A; Reis-Filho JS; Weigelt B
J Pathol; 2015 Oct; 237(2):179-89. PubMed ID: 26095796
[TBL] [Abstract][Full Text] [Related]
17. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer.
Ross JS; Wang K; Elkadi OR; Tarasen A; Foulke L; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Chmielecki J; Ali SM; Elvin J; Morosini D; Miller VA; Stephens PJ
J Clin Pathol; 2014 Sep; 67(9):772-6. PubMed ID: 24978188
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
[TBL] [Abstract][Full Text] [Related]
19. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Frampton GM; Ali SM; Rosenzweig M; Chmielecki J; Lu X; Bauer TM; Akimov M; Bufill JA; Lee C; Jentz D; Hoover R; Ou SH; Salgia R; Brennan T; Chalmers ZR; Jaeger S; Huang A; Elvin JA; Erlich R; Fichtenholtz A; Gowen KA; Greenbowe J; Johnson A; Khaira D; McMahon C; Sanford EM; Roels S; White J; Greshock J; Schlegel R; Lipson D; Yelensky R; Morosini D; Ross JS; Collisson E; Peters M; Stephens PJ; Miller VA
Cancer Discov; 2015 Aug; 5(8):850-9. PubMed ID: 25971938
[TBL] [Abstract][Full Text] [Related]
20. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.
Ali SM; Sanford EM; Klempner SJ; Rubinson DA; Wang K; Palma NA; Chmielecki J; Yelensky R; Palmer GA; Morosini D; Lipson D; Catenacci DV; Braiteh F; Erlich R; Stephens PJ; Ross JS; Ou SH; Miller VA
Oncologist; 2015 May; 20(5):499-507. PubMed ID: 25882375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]